Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Multi-Center, Placebo-Controlled, Masked Study to Evaluate the Clinical Efficacy and Safety of Fusidic Acid 1% Viscous Topical Antibiotic Eye Drops for the Treatment of Suspected Bacterial Conjunctivitis

NCT06911424 is registered in ClinicalTrials.gov with Baxis Pharmaceuticals, Inc. as lead sponsor.

NCT NCT06911424
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06911424 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Multi-Center, Placebo-Controlled, Masked Study to Evaluate the Clinical Efficacy and Safety of Fusidic Acid 1% Viscous Topical Antibiotic Eye Drops for the Treatment of Suspected Bacterial Conjunctivitis
Lead sponsor
Baxis Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
March 21, 2025
Completion date
March 23, 2026
Enrollment
400 (estimated)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

bacterial conjunctivitis